<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835328</url>
  </required_header>
  <id_info>
    <org_study_id>2008-10-6256</org_study_id>
    <nct_id>NCT00835328</nct_id>
  </id_info>
  <brief_title>Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia</brief_title>
  <official_title>Role of GLP-1 In Congenital Hyperinsulinism: Effect Of Exendin-(9-39)On Glucose Requirements To Maintain Euglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diva De Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of exendin-(9-39)on glucose requirements
      to maintain euglycemia in infants with congenital hyperinsulinism unresponsive to medical
      therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label sudy to examine the effect of exendin-(9-39)on glucose requirements to
      maintain euglycemia in infants with congenital hyperinsulinism unresponsive to medical
      therapy and to determine therapeutic plasma levels,plasma half life and pharmacokinetics of
      exendin-(9-39)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose infusion rate during the last 2 hours of infusion of exendin-(9-39)</measure>
    <time_frame>7-9 hours after start of infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose 1 hour after initiation of infusion,</measure>
    <time_frame>1 hour after start of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Level</measure>
    <time_frame>0,1,5,9,hour during 9 hour infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of exendin-(9-39)</measure>
    <time_frame>1,5,9, +15,10,12,14 hour during and post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Betahydroxybutyrate levels</measure>
    <time_frame>0,1,5,9, during 9 hour infusion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety variables</measure>
    <time_frame>2 days (baseline, study end)</time_frame>
    <description>12 lead electrocardiograms,laboratory safety test(hematology, chemistry and urinalysis)</description>
  </other_outcome>
  <other_outcome>
    <measure>safety variable</measure>
    <time_frame>9 hours</time_frame>
    <description>Vital signs, adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>safety variables</measure>
    <time_frame>baseline</time_frame>
    <description>physical examination</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>exendin-(9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous infusion of normal saline over 9 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin-(9-39)</intervention_name>
    <description>exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours</description>
    <arm_group_label>exendin-(9-39)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>normal saline Intravenous infusion over 9 hours</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of congenital hyperinsulinism (based on clinical criteria:
             insulin, beta hydroxybutyrate, and/or free fatty acid plasma levels at the time of
             hypoglycemia, and/or glycemic response to glucagon at the time of hypoglycemia)

          -  Age: from birth to 12 months

          -  Failure to respond to diazoxide (defined as the failure to maintain blood glucose and
             octreotide (defined as the failure to maintain blood glucose ≥ 70 mg/dL without
             supraphysiologic rates of glucose infusion&gt; 4-5 mg/Kg/min)

        Exclusion Criteria:

          -  Evidence of a medical condition that might alter results, including active infection,
             kidney failure, severe liver dysfunction, severe respiratory or cardiac failure

          -  Current therapy at the time of initiation of study procedures with medications that
             affect glucose metabolism, such as high dose glucocorticoids, ß-agonists, glucagon,
             diazoxide and octreotide. Subjects will be eligible to participate 4 hours after
             glucagon is discontinued, 24 hours after the last dose of octreotide and 72 hours
             after last dose of diazoxide,

          -  Subjects with suspected Beckwith-Wiedemann syndrome or other syndromic forms of
             congenital hyperinsulinism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diva D De Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Givler, BS,CCRC</last_name>
    <phone>267-426-7622</phone>
    <email>givler@email.chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Givler, BS,CCRC</last_name>
      <phone>267-426-7622</phone>
      <email>givler@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Diva D De Leon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles A Stanley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Diva De Leon</investigator_full_name>
    <investigator_title>M.D. Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>hyperinsulinism</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>ATP- sensitive potassium channel (KATP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

